

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Firazyr (icatibant)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Firazyr (icatibant)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Firazyr (icatibant) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hereditary angioedema; **AND**
- II. Individual is using for treatment of acute attacks (not prophylaxis); **AND**
- III. Individual is 18 years of age or older; **AND**
- IV. Diagnosis is confirmed by a C4 level below the lower limit of normal as defined by the laboratory performing the test **AND** one of the following:
 - A. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test with documentation provided; **OR**
 - B. C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test with documentation provided; **AND**
- V. Individual has a history of moderate or severe attacks such as airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, or painful facial distortion.

Requests for Firazyr may not be approved for all other indications not included above.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 8, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients with Type I and Type II HAE. NCT02586805 (HELP Study). Available at <https://www.clinicaltrials.gov/ct2/show/study/NCT02586805>. Accessed on July 8, 2019.

CRX-ALL-0498-20

PAGE 1 of 2 02/05/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
6. Riedl MA, Bernstein JA, Craig T, et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. *Clin Transl Allergy*. 2017;7:36.
7. Riedl MA. Creating a Comprehensive Treatment Plan for Hereditary Angioedema. *Immunol Allergy Clin N Am*. 2013; 33 (4): 471-485. doi:10.1016/j.iac.2013.07.003.
8. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency. *J Allergy Clin Immunol: In Practice*. 2013; 1:458-67. doi:10.1016/j.jaip.2013.07.002.
9. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. *J Allergy Clin Immunol*. 2013; 131(6):1491-1493.e1-e25. Available from: [http://www.jacionline.org/article/S0091-6749\(13\)00523-X/pdf](http://www.jacionline.org/article/S0091-6749(13)00523-X/pdf). Accessed on: July 8, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.